-- BiolineRx Poised for Record Jump After Deal With Genoscience
-- B y   S h o s h a n n a   S o l o m o n
-- 2012-01-24T14:04:28Z
-- http://www.bloomberg.com/news/2012-01-24/biolinerx-poised-for-record-jump-after-deal-with-genoscience.html
BioLineRx Ltd. (BLRX)  was headed for the
biggest surge on record after the Israeli company that develops
therapeutic pharmaceutical drugs signed a deal with France’s
Genoscience to develop and commercialize a treatment.  The shares surged 33 percent, the most on a closing basis
since February 2007 when Bloomberg started tracking them, to
1.598 shekels at 3:57 p.m. in  Tel Aviv .  BioLineRx signed an “exclusive license agreement” with
Genoscience for its BL-8020 oral treatment for Hepatitis C, it
said in a filing with the Tel Aviv Stock Exchange.  To contact the reporter on this story:
Shoshanna Solomon in Tel Aviv at 
 ssolomon22@bloomberg.net   To contact the editor responsible for this story:
Claudia Maedler at 
 cmaedler@bloomberg.net  